Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma

Nirmish Singla; Vitaly Margulis

doi:10.1016/j.eururo.2020.09.013

Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e28
Journal	European urology
Volume	79
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2020.09.013
State	Published - Jan 2021

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2020.09.013

Cite this

Singla, N., & Margulis, V. (2021). Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma. European urology, 79(1), e28. https://doi.org/10.1016/j.eururo.2020.09.013

Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma. / Singla, Nirmish; Margulis, Vitaly.
In: European urology, Vol. 79, No. 1, 01.2021, p. e28.

Research output: Contribution to journal › Letter › peer-review

Singla, N & Margulis, V 2021, 'Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma', European urology, vol. 79, no. 1, pp. e28. https://doi.org/10.1016/j.eururo.2020.09.013

Singla N, Margulis V. Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma. European urology. 2021 Jan;79(1):e28. doi: 10.1016/j.eururo.2020.09.013

Singla, Nirmish ; Margulis, Vitaly. / Re : Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma. In: European urology. 2021 ; Vol. 79, No. 1. pp. e28.

@article{12f1742da76c4d5aa3da7babd5fc6662,

title = "Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma",

author = "Nirmish Singla and Vitaly Margulis",

year = "2021",

month = jan,

doi = "10.1016/j.eururo.2020.09.013",

language = "English (US)",

volume = "79",

pages = "e28",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Re

T2 - Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268–77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma

AU - Singla, Nirmish

AU - Margulis, Vitaly

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85092675047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092675047&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.09.013

DO - 10.1016/j.eururo.2020.09.013

M3 - Letter

C2 - 33008662

AN - SCOPUS:85092675047

SN - 0302-2838

VL - 79

SP - e28

JO - European urology

JF - European urology

IS - 1

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this